Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals to Present at the Cowen and Company 33rd Annual Healthcare Conference
NEW YORK, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that Mark Pruzanski,
View HTML
Toggle Summary Intercept Pharmaceuticals to Present at Leerink Swann 2013 Global Healthcare Conference
NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that Mark Pruzanski, MD,
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Initiation of Phase 2 NASH Trial of OCA in Japan
NEW YORK, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that its partner
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Completion of Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial
NEW YORK, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it has completed
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Completion of Enrollment in FLINT
NEW YORK, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, has been informed by the National Institute of
View HTML
Toggle Summary Intercept Pharmaceuticals to Present Phase 2a Portal Hypertension Data at AASLD's Liver Meeting
NEW YORK, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced initial results from PESTO, an
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Intercept Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Pricing of Initial Public Offering
Intercept Pharmaceuticals Announces Pricing of Initial Public Offering NEW YORK, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases,
View HTML
Toggle Summary Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering New York, NY, September 4, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat
View HTML
Toggle Summary Intercept Pharmaceuticals Closes $30 Million Series C Financing
OrbiMed’s Jonathan Silverstein and Klaus Veitinger Join Board of Directors
View HTML